Role of fatty acids in pathogenetic mechanisms of NAFLD progression among type 2 diabetes patients
DOI:
https://doi.org/10.12775/JEHS.2020.10.11.025Keywords
diabetes mellitus type two, nonalcoholic fatty liver disease, fibrosis, fatty acidsAbstract
The goal of our case-control research was to study the associations between speed progression of NAFLD and the level of fatty acids among patients with the type 2 diabetes. All patients were divided into two groups: with speed (n=38) and slow (n=44) progression of fibrosis. We studied the level of saturated, monounsaturated and polyunsaturated fatty acids and their rate. Our study showed higher median value of sum of saturated fatty acids level in the group of patients with speed progression of fibrosis (51,6% and 45,75%, p=0,001) and lower median value of arachidonic acids than in the group of patients with slow progression of fibrosis (10,5 and11,5 inthe group of slow fibrosis progression, р=0,049). In the group of patients with speed fibrosis progression saturated fatty acids prevailed unsaturated fatty acids (Ме=1,02). According to our data, the risk factor of speed progression of fibrosis among patients with type 2 diabetes and NAFLD, is the rate of saturated and unsaturated fatty acids. We found the significant associations between the rate of saturated and unsaturated fatty acids and the speed progression of fibrosis (OR 77,3; р=0,004).
Abbreviations: BMI, body mass index, IR, insulin resistance, NAFLD, nonalcoholic fatty liver disease, OR, odds ratio, FFA, free fatty acids, FA, fatty acids, LDL, low density lipoproteins, RPF, median rate of fibrosis progression, TG, triglycerides
References
Birkenfeld AL, and Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 59: 713–723, 2014. 10.1002/hep.26672
Ahmed A, Wong RJ, and Harrison SA. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. Clin Gastroenterol Hepatol 13: 2062–2070, 2015. 10.1016/j.cgh.2015.07.029
Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, and Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Investig 115: 1343–1351, 2005.
Lewis GF, Carpentier A, Adeli K, and Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev23: 201–229, 2002.
Saltiel AR, and Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799–806, 2001
Bradbury MW. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. American journal of physiology Gastrointestinal and liver physiology 290: G194–G198, 2006.
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, and Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 150: 2001.
Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, and Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 1387–1395, 2004. 10.1002/hep.20466
Grevengoed TJ, Klett EL, and Coleman RA. Acyl-CoA metabolism and partitioning. Annu Rev Nutr 34: 1–30, 2014.
Schroeder F, Petrescu AD, Huang H, Atshaves BP, McIntosh AL, Martin GG, Hostetler HA, Vespa A, Landrock D, Landrock KK, Payne HR, and Kier AB. Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription. Lipids 43: 1–17, 2008
Alves-Bezerra M, Cohen DE. Triglyceride metabolism in the liver Compr Physiol. 2019; 8(1): 1–8. doi:10.1002/cphy.c170012
Alonso C, Fernández-Ramos D, Varela-Rey M, Martínez-Arranz I, Navasa N, Van Liempd SM, Lavín Trueba JL, [et al]. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. Gastroenterology. 2017;152:1449-61.
European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–402.
Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clinics in Liver Disease. 2007;11(1):191–207.
Tarantino G, Conca P, Pasanisi F, Ariello M, Mastrolia M, Arena A, Tarantino M, [et al.]. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol. 2009; 21(5):504-11. doi: 10.1097/MEG.0b013e3283229b40
Hegazy M, Elsayed NM, Ali HM, Hassan HG, Rashed. Diabetes Mellitus, Nonalcoholic Fatty Liver Disease, and Conjugated Linoleic Acid (Omega 6): What Is the Link? J Diabetes Res. 2019;2019:5267025.
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 439
Number of citations: 0